Article
BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
Radiation oncology (London, England) - 18 Sept 2021
Wolfe Adam R, Chablani Priyanka, Siedow Michael R, Miller Eric D, Walston Steve, Kendra Kari L, Wuthrick Evan, Williams Terence M
Abstract excerpt
BACKGROUND: In patients with stage III melanoma, the use of adjuvant radiation therapy (RT) after lymph node dissection (LND) may be currently considered in selected high-risk patients to improve tumor control. Melanomas harbor BRAF mutations (BRAF+) in 40-50% of cases, the majority of which are on the V600E residue. This study sought to compare the clinical outcomes after RT between patients with BRAF+ and BRAF-...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.